Vnitr Lek 2024, 70(7):446-451 | DOI: 10.36290/vnl.2024.087

Atrial fibrillation in patients with arterial hypertension and novel European Guidelines

Štěpán Havránek
II. interní klinika kardiologie a angiologie 1. lékařské fakulty Univerzity Karlovy a Všeobecné fakultní nemocnice v Praze

Atrial fibrillation and arterial hypertension are frequent diagnoses in internal medicine and are often combined. The presence of arterial hypertension, especially insufficiently corrected, is a risk factor for the occurrence of atrial fibrillation itself, but also a factor in the progression of the disease and a risk factor for the failure of atrial fibrillation rhythm control treatment. Arterial hypertension also increases the risk of complications of atrial fibrillation, especially thromboembolic events, and increases the risk of bleeding during anticoagulant treatment. The therapy of atrial fibrillation and arterial hypertension overlaps at certain points and complements at others.

Keywords: atrial fibrillation, arterial hypertension, risk factors, complications.

Accepted: October 24, 2024; Published: November 14, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Havránek Š. Atrial fibrillation in patients with arterial hypertension and novel European Guidelines. Vnitr Lek. 2024;70(7):446-451. doi: 10.36290/vnl.2024.087.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024. Online ahead. Go to original source... Go to PubMed...
    2. Van Gelder IC, Rienstra M, Bunting KV, et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024. Online ahead. Go to original source... Go to PubMed...
    3. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2023;44(37):3627-39. Go to original source... Go to PubMed...
    4. Deshmukh PM, Krishnamani R, Romanyshyn M, et al. Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. Int J Mol Med. 2004;13:455-458. Go to original source...
    5. Medi C, Kalman JM, Haqqani H, et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol. 2009;53:1791-1797. Go to original source... Go to PubMed...
    6. Pinho-Gomes AC, Azevedo L, Copland E, et al. Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: an individual participant data meta-analysis. PLoS Med 2021;18:e1003599. Go to original source... Go to PubMed...
    7. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-73. Go to original source... Go to PubMed...
    8. Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J. 2018;39:3999-4008. Go to original source... Go to PubMed...
    9. Gupta D, Rienstra M, van Gelder IC, Fauchier L. Atrial fibrillation: better symptom control with rate and rhythm management. Lancet Reg Health-Eu. 2024;37. Go to original source... Go to PubMed...
    10. Koldenhof T, Van Gelder IC, van de Lande ME, et al. High heart rates during paroxysmal atrial fibrillation: continuous rhythm monitoring data of the RACE V study. Heart. 2024. Go to original source...
    11. Linz D, Andrade JG, Arbelo E, et al. Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference. Europace. 2024;26(4). Go to original source... Go to PubMed...
    12. Sterlinski M, Bunting K, Boriani G, et al. Design and deployment of the STEEER-AF trial to evaluate and improve guideline adherence: a cluster-randomized trial by the European Society of Cardiology and European Heart Rhythm Association. Europace. 2024;26(7). Go to original source... Go to PubMed...
    13. Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill Strategy in Secondary Cardiovascular Prevention. New Engl J Med. 2022;387(11):967-77. Go to original source... Go to PubMed...
    14. Hradec J. Adherence v české republice. Medicína po promoci 2019;20:1-7.
    15. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007 Aug;120(8):713-9. Go to original source... Go to PubMed...
    16. Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin. 2017 Oct;33(10):1783-1787. Go to original source... Go to PubMed...
    17. McEvoy JW, McCarthy CP, Bruno, RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal. 2024; 00:1-107. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.